Analysts Are Pretty Bullish … Marrone Bio Innovations (NASDAQ:MBII)

Earnings results for Marrone Bio Innovations (NASDAQ:MBII)

Marrone Bio Innovations, Inc. is expected* to report earnings on 08/16/2021 after market close. The report will be for the fiscal Quarter ending Jun 2021. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $0. The reported EPS for the same quarter last year was $-0.02.

Marrone Bio Innovations last announced its earnings data on May 12th, 2021. The basic materials company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The company earned $11.04 million during the quarter, compared to the consensus estimate of $11.06 million. Marrone Bio Innovations has generated ($0.12) earnings per share over the last year (($0.11) diluted earnings per share). Earnings for Marrone Bio Innovations are expected to grow in the coming year, from ($0.07) to ($0.01) per share. Marrone Bio Innovations has confirmed that its next quarterly earnings report will be published on Monday, August 16th, 2021. Marrone Bio Innovations will be holding an earnings conference call on Monday, August 16th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode “8750498”.

Analyst Opinion on Marrone Bio Innovations (NASDAQ:MBII)

4 Wall Street analysts have issued ratings and price targets for Marrone Bio Innovations in the last 12 months. Their average twelve-month price target is $3.50, predicting that the stock has a possible upside of 141.38%. The high price target for MBII is $4.00 and the low price target for MBII is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Marrone Bio Innovations has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $3.50, Marrone Bio Innovations has a forecasted upside of 141.4% from its current price of $1.45. Marrone Bio Innovations has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Marrone Bio Innovations (NASDAQ:MBII)

Marrone Bio Innovations does not currently pay a dividend. Marrone Bio Innovations does not have a long track record of dividend growth.

Insiders buying/selling: Marrone Bio Innovations (NASDAQ:MBII)

In the past three months, Marrone Bio Innovations insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $149,962.00 in company stock. Only 4.67% of the stock of Marrone Bio Innovations is held by insiders. Only 34.08% of the stock of Marrone Bio Innovations is held by institutions.

Earnings and Valuation of Marrone Bio Innovations (NASDAQ:MBII

Earnings for Marrone Bio Innovations are expected to grow in the coming year, from ($0.07) to ($0.01) per share. The P/E ratio of Marrone Bio Innovations is -13.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Marrone Bio Innovations is -13.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Marrone Bio Innovations has a P/B Ratio of 7.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here